Roles of the immune system in cancer: From tumor initiation to metastatic progression

Genes and Development

Volumn 32, Issue 19-20, 2018, Pages 1267-1284

  Gonzalez, Hugo ^a   Hagerling, Catharina ^a,b   Werb, Zena ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cancer heterogeneity; Disseminated tumor cells; Immune cross talk; Metastasis associated immune cells; Patient derived xenograft; Tumor associated macrophages

Indexed keywords

ANTIGEN RECOGNITION; B LYMPHOCYTE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MALIGNANT NEOPLASM; METASTASIS; MOLECULAR INTERACTION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 85054060858     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/GAD.314617.118     Document Type: Review

References (234)

1. Abraham D, Zins K, Sioud M, Lucas T, Schafer R, Stanley ER, Aharinejad S. 2010. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer 126: 1339–1352.
2. Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirstrom K, Leandersson K. 2017. Infiltration of γδ T cells, IL-17 T cells and FoxP3 T cells in human breast cancer. Cancer Biomark 20: 395–409.
3. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al. 2010. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121–134.
4. Andrews DM, Sullivan LC, Baschuk N, Chan CJ, Berry R, Cotter-ell CL, Lin J, Halse H, Watt SV, Poursine-Laurent J, et al. 2012. Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nat Immunol 13: 1171–1177.
5. Askeland EJ, Newton MR, O’Donnell MA, Luo Y. 2012. Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012: 181987.
6. Balkwill F, Mantovani A. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539–545.
7. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, et al. 2013. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145: 166–175 e168.
8. Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. Nature 501: 355–364.
9. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, et al. 2011. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 17: 4558–4567.
10. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737–744.
11. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al. 2012. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18: 1224–1231.
12. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. 1991. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349: 329–331.
13. Boger C, Behrens HM, Kruger S, Rocken C. 2017. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? Oncoimmunology 6: e1293215.
14. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M. 2014. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515: 130–133.
15. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. 2013. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210: 2435–2466.
16. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244–265.
17. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrer-izo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis ESC. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172: 1022–1037.e14.
18. Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, Kumar R. 2010. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother 59: 303–312.
19. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26: 938.
20. Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinska E, Caldas C, Chang DK, et al. 2017. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 17: 254–268.
21. Campbell DJ. 2015. Control of regulatory T cell migration, function, and homeostasis. Eur J Immunol 195: 2507–2513.
22. Casbon AJ, Lohela M, Werb Z. 2015. Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors. Oncoimmunology 4: e1008871.
23. Cerwenka A, Lanier LL. 2016. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 16: 112–123.
24. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12: 721–727.
25. Chambers AF, Werb Z. 2015. Invasion and metastasis—recent advances and future challenges. J Mol Med (Berl) 93: 361–368.
26. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C. 2014. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci 111: 5664–5669.
27. Chen Q, Ross AC. 2012. All-trans-retinoic acid and the glycolipid α-galactosylceramide combined reduce breast tumor growth and lung metastasis in a 4T1 murine breast tumor model. Nutr Cancer 64: 1219–1227.
28. Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, Nishio J, Negishi H, Tamura T, Saijo S, et al. 2014. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. eLife 3: e04177.
29. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. 1992. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12: 1463–1466.
30. Chong TW, Goh FY, Sim MY, Huang HH, Thike AA, Lim WK, Teh BT, Tan PH. 2015. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. J Clin Pathol 68: 200–205.
31. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al. 2018. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359: 582–587.
32. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cas-cinelli N. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303–1310.
33. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79: 2320–2328.
34. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels L, Jonkers J, et al. 2015. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522: 345–348.
35. Colonna M, Spies T, Strominger JL, Ciccone E, Moretta A, Moretta L, Pende D, Viale O. 1992. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci 89: 7983–7985.
36. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Gian-nias B, Bourdeau F, Kubes P, Ferri L. 2013. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 123: 3446–3458.
37. Cools-Lartigue J, Spicer J, Najmeh S, Ferri L. 2014. Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci 71: 4179–4194.
38. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et al. 2015. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17: 816–826.
39. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420: 860–867.
40. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54–67.
41. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, et al. 2011. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514–1520.
42. De Silva NS, Klein U. 2015. Dynamics of B cells in germinal centres. Nat Rev Immunol 15: 137–148.
43. de Visser KE, Korets LV, Coussens LM. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411–423.
44. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208: 1989–2003.
45. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1: 119–126.
46. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165–171.
47. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26: 4410–4417.
48. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, et al. 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13: 879–886.
49. Di Giacomo AM, Valente M, Covre A, Danielli R, Maio M. 2017. Immunotherapy targeting immune check-point(s) in brain metastases. Cytokine Growth Factor Rev 36: 33–38.
50. Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F. 2008. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 35: 317–321.
51. Doherty MR, Smigiel JM, Junk DJ, Jackson MW. 2016. Cancer stem cell plasticity drives therapeutic resistance. Cancers 8: E8.
52. Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Mac-eda B, Gomez-Aguado F, Corcuera MT, Sanchez-Mateos P, Corbi AL. 2011. Dendritic cell-specific ICAM-3-grabbing non-integrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol 186: 2192–2200.
53. Donadon M, Hudspeth K, Cimino M, Di Tommaso L, Preti M, Tentorio P, Roncalli M, Mavilio D, Torzilli G. 2017. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival. J Gastrointest Surg 21: 1226–1236.
54. Donskov F. 2013. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 23: 200–207.
55. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A. 2006. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165: 114–120.
56. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojta-hedi Z, Ghaderi A, Amani D. 2012. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77: 306–311.
57. Espinosa V, Jhingran A, Dutta O, Kasahara S, Donnelly R, Du P, Rosenfeld J, Leiner I, Chen CC, Ron Y, et al. 2014. Inflammatory monocytes orchestrate innate antifungal immunity in the lung. PLoS Pathog 10: e1003940.
58. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359–E386.
59. Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, et al. 2015. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522: 349–353.
60. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015–3029.
61. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: ‘N1’ versus ‘N2’ TAN. Cancer Cell 16: 183–194.
62. Fridman WH, Pages F, Sautes-Fridman C, Galon J. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306.
63. Frisch M, Biggar RJ, Engels EA, Goedert JJ, Group AI-CMRS. 2001. Association of cancer with AIDS-related immunosup-pression in adults. JAMA 285: 1736–1745.
64. Frydrychowicz M, Boruczkowski M, Kolecka-Bednarczyk A, Dworacki G. 2017. The dual role of treg in cancer. Scand J Immunol 86: 436–443.
65. Furudate S, Fujimura T, Kambayashi Y, Hidaka T, Hashimoto A, Aiba S. 2016. Sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities. Case Rep Oncol 9: 644–649.
66. Gabrilovich DI. 2017. Myeloid-derived suppressor cells. Cancer Immunol Res 5: 3–8.
67. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096–1103.
68. Gasser S, Orsulic S, Brown EJ, Raulet DH. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186–1190.
69. Gebremeskel S, Clattenburg DR, Slauenwhite D, Lobert L, Johnston B. 2015. Natural killer T cell activation overcomes imim munosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. Oncoimmunology 4: e995562. munosuppression
70. Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, et al. 2017. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552: 116–120.
71. Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, Mandelboim O. 2012. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol 188: 2509–2515.
72. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. 2016. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17: 976–983.
73. Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, Mirabolfathinejad SG, Dickey BF, Zhou Q, Moghaddam SJ. 2013. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer 12: 154.
74. Gonzalez H, Robles I, Werb Z. 2018. Innate and acquired immune surveillance in the postdissemination phase of metastasis. FEBS J 285: 654–664.
75. Gopinathan A, Morton JP, Jodrell DI, Sansom OJ. 2015. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech 8: 1185–1200.
76. Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruz-zelli L, et al. 2017. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 17: 286–301.
77. Governa V, Trella E, Mele V, Tornillo L, Amicarella F, Cremonesi E, Muraro MG, Xu H, Droeser R, Daster SR, et al. 2017. The interplay between neutrophils and CD8 T cells improves survival in human colorectal cancer. Clin Cancer Res 23: 3847–3858.
78. Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. 2011. Tumor entrained neutrophils inhibit seeding in the pre-metastatic lung. Cancer Cell 20: 300–314.
79. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140: 883–899.
80. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571–580.
81. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, et al. 2017. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543: 428–432.
82. Gupta GP, Massague J. 2006. Cancer metastasis: building a framework. Cell 127: 679–695.
83. Gupta SC, Kim JH, Prasad S, Aggarwal BB. 2010. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405–434.
84. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. 2007. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22: 2283–2287.
85. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al. 2011. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71: 5670–5677.
86. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Car-mona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. 2016. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29: 587–601.
87. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wol-chok JD, Hersey P, Joseph RW, Weber JS, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.
88. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.
89. Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, Herrley E, Rasquinha N, McArdle S, Wu R, et al. 2015. Patrolling monocytes control tumor metastasis to the lung. Science 350: 985–990.
90. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. 2000. Eradication of established tumors by CD8 T cell adoptive immunotherapy. Immunity 13: 265–276.
91. Headley MB, Bins A, Nip A, Roberts EW, Looney MR, Gerard A, Krummel MF. 2016. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531: 513–517.
92. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.
93. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, et al. 2008. Batf3 deficiency reveals a critical role for CD8α dendritic cells in cytotoxic T cell immunity. Science 322: 1097–1100.
94. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. 2011. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One 6: e20702.
95. Hosseini H, Obradovic MM, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, et al. 2016. Early dissemination seeds metastasis in breast cancer. Nature 540: 552–558.
96. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al. 2010. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16: 219–223.
97. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. 2013. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 19: 6074–6083.
98. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94: 1134–1142.
99. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, et al. 2000. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60: 3333–3337.
100. Hylander BL, Punt N, Tang H, Hillman J, Vaughan M, Bshara W, Pitoniak R, Repasky EA. 2013. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11: 110.
101. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. 2013. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 210: 2057–2069.
102. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. 2016. Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol 38: 52–58.
103. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. 2000. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577–583.
104. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, et al. 2012. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122: 3127–3144.
105. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
106. Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, et al. 2017. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170: 927–938.e20.
107. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, DuPage M, Tammela T, Kerper NR, Farago AF, et al. 2015. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43: 579–590.
108. Jung J, Seol HS, Chang S. 2018. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat 50: 1–10.
109. Kalams SA, Walker BD. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188: 2199–2204.
110. Karlhofer FM, Ribaudo RK, Yokoyama WM. 1992. MHC class I alloantigen specificity of Ly-49 IL-2-activated natural killer cells. Nature 358: 66–70.
111. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. 2013. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24: 631–644.
112. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. 2012. The association of pre-treat-ment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48: 202–208.
113. Kessenbrock K, Plaks V, Werb Z. 2010. Matrix metalloprotei-nases: regulators of the tumor microenvironment. Cell 141: 52–67.
114. Khaghanzadeh N, Erfani N, Ghayumi MA, Ghaderi A. 2010. CTLA4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet 196: 171–174.
115. Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. 2016. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol 28: 373–382.
116. Kitamura T, Qian BZ, Pollard JW. 2015. Immune cell promotion of metastasis. Nat Rev Immunol 15: 73–86.
117. Kolaczkowska E, Kubes P. 2013. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13: 159–175.
118. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futat-suyama K, Toma H, Tanabe K. 2006. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97: 780–786.
119. Kreso A, Dick JE. 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14: 275–291.
120. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. 2016. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37: 208–220.
121. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K. 2005. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13: 1153–1158.
122. Lakatos PL, Lakatos L. 2008. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14: 3937–3947.
123. Lambert AW, Pattabiraman DR, Weinberg RA. 2017. Emerging biological principles of metastasis. Cell 168: 670–691.
124. Lanier LL. 2005. Missing self, NK cells, and The White Album. J Immunol 174: 6565.
125. Lavin Y, Mortha A, Rahman A, Merad M. 2015. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol 15: 731–744.
126. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al. 2017. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169: 750–765.e17.
127. Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. 2015. Tissue-specific distribution of iNKT cells impacts their cytokine response. Immunity 43: 566–578.
128. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. 1991. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253: 199–202.
129. Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, et al. 2012a. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res 72: 1964–1974.
130. Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. 2012b. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol 189: 1826–1834.
131. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. 2016. IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov 6: 400–413.
132. Lu X, Kang Y. 2009. Chemokine (C-C motif) ligand 2 engages CCR2 stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284: 29087–29096.
133. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. 2013. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38: 729–741.
134. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de Stan-china E, Massague J. 2016. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165: 45–60.
135. Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW, Fine HA. 1995. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 41: 227–235.
136. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555.
137. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. 2017. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14: 399–416.
138. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH. 2014. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122: 91–128.
139. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, et al. 2018. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554: 544–548.
140. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32: 790–802.
141. Massague J. 2008. TGFβ in cancer. Cell 134: 215–230.
142. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400–404.
143. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et al. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512–526.
144. McGranahan N, Swanton C. 2015. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27: 15–26.
145. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351: 1463–1469.
146. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. 2017. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171: 1259–1271 e1211.
147. McIntire RH, Morales PJ, Petroff MG, Colonna M, Hunt JS. 2004. Recombinant HLA-G5 and-G6 drive U937 myelomonocytic cell production of TGF-β1. J Leukoc Biol 76: 1220–1228.
148. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, et al. 2016. Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. J Cancer 7: 1095–1104.
149. Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, Wu J, Tomlinson S, Howe PH, Yang Y, et al. 2016. Surface expression of TGFβ docking receptor GARP promotes oncogenesis and immune tolerance in breast cancer. Cancer Res 76: 7106–7117.
150. Mildner A, Jung S. 2014. Development and function of dendritic cell subsets. Immunity 40: 642–656.
151. Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. 2005. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 26: 668–675.
152. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, et al. 2009. A phase I–II study of α-galactosylceramide-pulsed IL-2/ GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492–2501.
153. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803–1813.
154. Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, et al. 2016. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22: 1402–1410.
155. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, et al. 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic pep-tide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci 92: 8078–8082.
156. Nakatsumi H, Matsumoto M, Nakayama KI. 2017. Noncanonical pathway for regulation of CCL2 expression by an mTORC1– FOXK1 axis promotes recruitment of tumor-associated macrophages. Cell Rep 21: 2471–2486.
157. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332.
158. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. 2013. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 4: 129.
159. Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41: 49–61.
160. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. 2006. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 18: 1591–1602.
161. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A. 2011. Tu-mor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res 71: 3505–3515.
162. O’Sullivan C, Lewis CE, Harris AL, McGee JO. 1993. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 342: 148–149.
163. O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, et al. 2012. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 209: 1869–1882.
164. Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB, et al. 2017. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22: 1392–1399.
165. Palucka AK, Coussens LM. 2016. The basis of oncoimmunology. Cell 164: 1233–1247.
166. Papayannopoulos V. 2018. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18: 134–147.
167. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264.
168. Pardoll DM, Topalian SL. 1998. The role of CD4 T cell responses in antitumor immunity. Curr Opin Immunol 10: 588–594.
169. Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, Schott AF, Kinugasa-Katayama Y, Lee Y, Won NH, et al. 2016. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 8: 361ra138.
170. Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, et al. 2017. Identification of essential genes for cancer immunotherapy. Nature 548: 537–542.
171. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Kora-lov SB, Bar-Sagi D. 2016. IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov 6: 247–255.
172. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222–225.
173. Qian BZ, Zhang H, Li J, He T, Yeo EJ, Soong DY, Carragher NO, Munro A, Chang A, Bresnick AR, et al. 2015. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J Exp Med 212: 1433–1448.
174. Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423–1437.
175. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, et al. 2014. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118: 109–116.
176. Raulet DH. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781–790.
177. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. 2013. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31: 413–441.
178. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124–128.
179. Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF. 2016. Critical role for CD103/CD141 dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30: 324–336.
180. Roh-Johnson M, Bravo-Cordero JJ, Patsialou A, Sharma VP, Guo P, Liu H, Hodgson L, Condeelis J. 2014. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intrava-sation. Oncogene 33: 4203–4212.
181. Rollins BJ, Sunday ME. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 11: 3125–3131.
182. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, et al. 2014. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32: 364–372.
183. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR Jr, et al. 2008. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28: 546–558.
184. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. 2014. Macrophage IL-10 blocks CD8 T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26: 623–637.
185. Samraj AN, Pearce OM, Laubli H, Crittenden AN, Bergfeld AK, Banda K, Gregg CJ, Bingman AE, Secrest P, Diaz SL, et al. 2015. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci 112: 542–547.
186. Santos PM, Butterfield LH. 2018. Dendritic cell-based cancer vaccines. J Immunol 200: 443–449.
187. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR. 2011. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci 108: 10662–10667.
188. Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Krieg-sheim A, Gomez-Cuadrado L, Canel M, Muir M, Ring JE, et al. 2015. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 163: 160–173.
189. Shalapour S, Karin M. 2015. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125: 3347–3355.
190. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.
191. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. 2007. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825–831.
192. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N. 2008. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18: 372–378.
193. Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, Khaled AR. 2017. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 97: 123–132.
194. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin 66: 7–30.
195. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desri-chard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: 2189–2199.
196. Speiser DE, Ho PC, Verdeil G. 2016. Regulatory circuits of T cell function in cancer. Nat Rev Immunol 16: 599–611.
197. Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, et al. 2014. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26: 880–895.
198. Steele CW, Karim SA, Leach JD, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, et al. 2016. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29: 832–845.
199. Sun WW, Xu ZH, Lian P, Gao BL, Hu JA. 2017. Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. Onco Targets Ther 10: 2413–2424.
200. Swanton C. 2012. Intratumor heterogeneity: evolution through space and time. Cancer Res 72: 4875–4882.
201. Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M. 2018. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 T cell trafficking. Proc Natl Acad Sci 115: E1540–E1549.
202. Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T. 2009. Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-meta-static mouse breast cancer model. Clin Exp Metastasis 26: 817–828.
203. Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R. 2016. Key role for neutrophils in radiation-induced antitumor immune responses: potentiation with G-CSF. Proc Natl Acad Sci 113: 11300–11305.
204. Tanaka A, Sakaguchi S. 2017. Regulatory T cells in cancer immunotherapy. Cell Res 27: 109–118.
205. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Canellas A, Hernando-Momblona X, et al. 2018. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554: 538–543.
206. Teng MW, Galon J, Fridman WH, Smyth MJ. 2015. From mice to humans: developments in cancer immunoediting. J Clin Invest 125: 3338–3346.
207. Thun MJ, Henley SJ, Patrono C. 2002. Nonsteroidal anti-inflam-matory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252–266.
208. Tohme S, Yazdani HO, Al-Khafaji AB, Chidi AP, Loughran P, Mowen K, Wang Y, Simmons RL, Huang H, Tsung A. 2016. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res 76: 1367–1380.
209. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
210. Topalian SL, Drake CG, Pardoll DM. 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27: 450–461.
211. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, et al. 2011. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71: 1263–1271.
212. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. 2016. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375: 2255–2262.
213. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. 2015. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194: 2985–2991.
214. Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T. 2010. Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102: 742–747.
215. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. 2015. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350: 972–978.
216. Verma B, Ritchie M, Mancini M. 2017. Development and applications of patient-derived xenograft models in humanized mice for oncology and immune-oncology drug discovery. Curr Protoc Pharmacol 78: 14.41.1–14.41.12.
217. Vesalainen S, Lipponen P, Talja M, Syrjanen K. 1994. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A: 1797–1803.
218. Voskoboinik I, Smyth MJ, Trapani JA. 2006. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6: 940–952.
219. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO. 1995. Molecular clones of the p58 NK cell receptor reveal immuno-globulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2: 439–449.
220. Walker LS, Sansom DM. 2015. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 36: 63–70.
221. Wang Q, Feng M, Yu T, Liu X, Zhang P. 2014. Intratumoral regulatory T cells are associated with suppression of colorectal carcinoma metastasis after resection through overcoming IL-17 producing T cells. Cell Immunol 287: 100–105.
222. Wang TT, Zhao YL, Peng LS, Chen N, Chen W, Lv YP, Mao FY, Zhang JY, Cheng P, Teng YS, et al. 2017. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF–PD-L1 pathway. Gut 66: 1900–1911.
223. Ward-Hartstonge KA, Kemp RA. 2017. Regulatory T-cell heterogeneity and the cancer immune response. Clin Transl Immunology 6: e154.
224. Wculek SK, Malanchi I. 2015. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528: 413–417.
225. Weitzenfeld P, Ben-Baruch A. 2014. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 352: 36–53.
226. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. 2016. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pre-treated advanced melanoma. J Clin Oncol 34: 1330–1338.
227. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammir-ante M, Varki N, Shabaik A, Howell S, Kane CJ, et al. 2014. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 12: 30.
228. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al. 2014. Transcriptome-based network analysis reveals a spec-spec- trum model of human macrophage activation. Immunity 40: 274–288.
229. Yang C, Lee H, Jove V, Deng J, Zhang W, Liu X, Forman S, Dellin-ger TH, Wakabayashi M, Yu H, et al. 2013. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One 8: e54029.
230. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Mar-tincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, et al. 2017. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32: 169–184.e7.
231. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, Sun X, Li GG, Hu QD, Fu QH, et al. 2016. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res 76: 818–830.
232. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. 2012. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7: e50946.
233. Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, et al. 2018. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gutr 67: 1845–1854.
234. Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. 2016. Mouse models in oncoimmunology. Nat Rev Cancer 16: 759–773.